1 / 18

Heart Protection Study: Statin Benefits for Reducing Cardiovascular Risk

The MRC/BHF Heart Protection Study focuses on the eligibility criteria and factorial treatment comparisons for individuals aged 40-80 years with increased risk of coronary heart disease. It highlights the benefits of simvastatin use in reducing major vascular events such as heart attack and stroke.

xander-finley
Download Presentation

Heart Protection Study: Statin Benefits for Reducing Cardiovascular Risk

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ELIGIBILITY: MRC/BHF Heart Protection Study • Increased risk of CHD death due to prior disease: • Myocardial infarction or other coronary heart disease; • Occlusive disease of non-coronary arteries; or • Diabetes mellitus or treated hypertension • Age 40-80 years • Total cholesterol >3.5 mmol/l (>135mg/dl) • Statin or vitamins not considered clearly indicated or contraindicated by patient’s own doctors

  2. FACTORIAL TREATMENT COMPARISONS

  3. STATIN USE: Compliance (≥ 80%) with study simvastatin or non-study statin use

  4. Average: - 0.96 ± 0.02 mmol/l - 37 ± 0.8 mg/dl

  5. SIMVASTATIN: Average LDL DIFFERENCE(mmol/l ± se) by BASELINE LDL

  6. (2.6 mmol/l) (3.4 mmol/l)

  7. SIMVASTATIN: Safety monitoring

  8. SIMVASTATIN: Main conclusions • After allowance for non-compliance, 40mg daily simvastatin safely reducesthe risk of heart attack, of stroke, and of revascularisation by at least one-third • 5 years of statin treatment typically prevents these “major vascular events” in about: • 100 of every 1000 with previous MI • 80 " " other CHD • 70 " " diabetes (age 40+) • 70 " " previous stroke • 70 " " other PVD irrespective of cholesterol level (or age, or sex, or other treatments)

More Related